(Q46340150)

21 December 2017

title

Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia (English)

1 reference

21 December 2017

1 reference

C Ohlsson

6

0 references

author name string

J Hammarsten

1

1 reference

21 December 2017

J-E Damber

2

1 reference

21 December 2017

M Karlsson

3

1 reference

21 December 2017

T Knutson

4

1 reference

21 December 2017

O Ljunggren

5

1 reference

21 December 2017

R Peeker

7

1 reference

21 December 2017

U Smith

8

1 reference

21 December 2017

D Mellström

9

1 reference

21 December 2017

publication date

30 September 2008

1 reference

21 December 2017

Prostate Cancer and Prostatic Diseases

published in

1 reference

21 December 2017

volume

12

1 reference

21 December 2017

issue

2

1 reference

21 December 2017

page(s)

160-165

1 reference

21 December 2017

Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

A critical evaluation of simple methods for the estimation of free testosterone in serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Nutrition, insulin, insulin-like growth factors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Circulating Insulin-like Growth Factor-I and Benign Prostatic Hyperplasia - A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Insulin-like growth factors and risk of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Sex hormones, inflammation and the metabolic syndrome: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Endogenous sex hormones and metabolic syndrome in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Central obesity as a risk factor for prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Metabolic factors associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Benign Prostatic Hyperplasia: Antecedents and Natural History

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Influence of Age and Endocrine Factors on the Volume of Benign Prostatic Hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Determination of prostate volume by transrectal ultrasound

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

A study of the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2008.50

31 March 2020

Identifiers

DOI

10.1038/PCAN.2008.50

1 reference

21 December 2017

1 reference

21 December 2017